Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Menopause may change how antidepressants work in women

NCT ID NCT07259525

Knowledge-focused Sponsor: Eskisehir Osmangazi University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how menopause changes the way the body processes escitalopram, a common antidepressant. Researchers will measure drug levels in the blood of 94 women aged 40-60 who are premenopausal or menopausal and taking the medication for depression or anxiety. The goal is to help doctors personalize dosing for better results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 94 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants are women aged 40 to 60 years who have been diagnosed with major depressive disorder and/or generalized anxiety disorder and are currently receiving escitalopram treatment. All participants were recruited from the Psychiatry Clinic of Eskişehir Osmangazi University.

Ages

40 to 60 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 40 years or older and 60 years or younger * Diagnosed with major depressive disorder and/or generalized anxiety disorder by an independent psychiatrist (not a member of the research team) * Prescribed escitalopram treatment by an independent psychiatrist (not a member of the research team) * Receiving escitalopram treatment for at least one month and on a stable dose for at least one week * Willing to participate in the study and provide informed consent * Additional inclusion criterion for the menopausal group: Amenorrhea for at least one year (consistent with menopause diagnosis) * Additional inclusion criteria for the premenopausal group: Having regular menstrual cycles and being in the luteal phase (within 14 days after ovulation) of the menstrual cycle Exclusion Criteria: * Diagnosis of intellectual disability, dementia, psychotic disorders, schizoaffective disorder, or bipolar disorder * Alcohol or substance use disorder * Diagnosis of hepatic failure, renal failure, or cardiac failure * Severe malnutrition * Presence of an active systemic infectious or inflammatory disease * Current use of hormone replacement therapy for menopause * Use of oral contraceptives * Pregnancy or breastfeeding * Use of medications known to affect escitalopram plasma concentration * Use of medications that affect the CYP2C19 enzyme * Detection of alleles other than the predominant CYP2C19\*1 genotype in genetic analyses

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Depression - major depressive disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

generalized anxiety disorder major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Depression - major depressive disorder General anxiety disorder Menopause Therapeutic drug monitoring (TDM)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Eskişehir Osmangazi University, Faculty of Medicine, Department of Psychiatry

    Eskişehir, 26040, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.